9-11 June 2020
Postillion Hotel Amsterdam,
Amsterdam, NL
THE INDUSTRY’S EUROPEAN MEETING FOR ANTIBODY AND PROTEIN THERAPEUTIC SCIENCE, TECHNOLOGY AND NETWORKING
Get the latest event updates
2019 Information
Stay tuned. 2020 information will be updated soon.
New Half-Day Workshops
- Morning - Bispecific Antibodies: New Strategies and Case Studies
- Afternoon - Antibody-drug Conjugates (ADCs): New Strategies and Case Studies
Drug Development Focus
- The 2019 program will have a strong “drug development” focus with more preclinical and clinical case studies and more sessions focused on moving drug programs from discovery through development and the lessons learned along the way
- 2 Concurrent Tracks allowing you to customize your learning experience
Networking Opportunities!
Networking App - All registered attendees receive access to our conference networking app, which allows you to view the full attendee list and schedule meetings before you arrive in Amsterdam
Networking Cocktail Reception - Located inside the exhibit hall, attendees can enjoy cocktails while viewing scientific posters, live exhibitor demonstrations, and exchange business cards with fellow attendees.
2019 Luminary Keynote Speakers to Inspire Your R&D Efforts
By the Numbers
250+
50+
30+
Get Global Recognition of Your Work by Presenting a Poster
Although the deadline for poster submissions is over, we have made accommodations for more space and there is still an opportunity to present a scientific poster on a space-available basis. So be sure to register and submit your poster as soon as possible to be included in the program.
Student Poster Winners
Congratulations to the Antibody Society Student/Postdoc Poster Winners!
Amiram Sananes, PhD Student, Ben-Gurion University
A selective, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy and imaging, developed by combinatorial engineering
Roberta Lotti, Post-doctoral Fellow, University of Modena and Reggio Emilia
Neutralization of soluble Fas Ligand (sFasL) blocks blister formation without immunosuppression in pemphigus: development of PC111, a new monoclonal anti-FasL antibody
Join This Growing List of 2019 Delegates...
2bind GmbH
4C Biomed Services LTD
AbCellera
AbCheck S R O
Ablexis & AlivaMab Discovery Services
Ablexis
Ablynx
Abveris Antibody
Abzena
AC Immune
Acrobiosystems
ADC Therapeutics Limited
Affimed GmbH
Affiris AG
Aldevron
AlivaMab Discovery Services
Alligator Bioscience AB
Amgen
Amsterdam UMC
Andrew Alliance
Antibody Solutions
Aragen Bioscience
Argenx
ATUM
Avacta Life Sciences
AvantGen
Avid Bioservices
BAC BV
Bayer AG
Beckman Coulter Life Sciences
Ben Gurion University
Benchling
Berkeley Lights, Inc.
Bicycle Therapeutics
Biocad
Bionova Scientific
Bio-Rad AbD Serotec GmbH
BioTechne
Birkbeck, University of London
Blue Heron Biotech, LLC
Boehringer Ingelheim
BPS Bioscience
Bruker
Calypso Biotech
Carterra
Charles River Laboratories
Chemical Computing Group
ChemPartner
Chinese Antibody Society
Christian-Albrechts-University Kiel
CovalX
Crown Bioscience Inc
Dragonflytx
emp Biotech GmbH
ERA Consulting UK lTD
Erasmus MC
Evotec SE
Evox Therapeutics Limited
Experimental Drug Development Centre
Faculty of Military Health Sciences
FairJourney Biologics
Ferring
F-star Biotechnology Ltd
Fujifilm Diosynth Biotechnologies
Fusion Antibodies
GBP
Geneious Biologics
Genentech
Genmab
GenScript
Glykos Finland Oy
GSK
Gyros Protein Technologies
H. Lundbeck A/S
Harbour BioMed
Hubrecht Institute
Humabs BioMed SA
IBET
Icosagen Cell Factory
IGEM Therapeutics Ltd
IGM Biosciences Inc
IGYXOS
Iksuda Therapeutics Ltd
Imcheck Therapeutics
Immunocore Ltd
ImmunoPrecise Antibodies
Imperial College London
Indian Institute of Science Bangal
Industrial Technology Research Institute
Institut Curie
Institut de Recherche Pierre Fabre
Institut Pasteur
Institute of Molecular and Cell Biology
Instituto Butantan
IONTAS
Isogenica
Iteos Therapeutics
JOINN Biologics US, Inc
KBI BioPharma
King's College London
Kymab Limited
Kyowa Hakko Kirin Co Ltd
LakePharma
Lancaster University
LAVA Therapeutics
Leiden University
Leukocare AG
LifeArc
Ligand
Ligand Pharmaceuticals
Lonza Biologics
LUMC
MabPlex
Maxcyte
Medicxi
MedImmune
Merus
Monash University
MorphoSys AG
Namocell
NanoCellect Biomedical
NaturalAntibody
Netherlands Cancer Institute
Novartis Pharma AG
NovImmune
Novo Nordisk Research Center China
NYU Langone Perlmutter Cancer Cente
Oslo University Hospital - Rikshospitale
Pall Biotech
Pall ForteBio
PerkinElmer
Pfizer
PhyNexus
ProImmune
Promega
Proteros Biostructures GmbH
Rapid Novor Inc
Ridgeview Diagnostics AB
Roche Custom Biotech
Roche Glycart
Roche Innovation Center Zurich
Salipro Biotech
Sanofi-Aventis Deutschland GmbH
Sapidyne Instruments
Seoul National University
Single Cell Technology
Sphere Fluidics Limited
Synaffix BV
Syngene International
Synthon Biopharmaceuticals BV
Takis
The Scripps Research Institute
The University of Texas at Austin
Thermo Fisher Scientific
Thomson Instrument
Trianni
Twist Bioscience
UCB
UCL Cancer Institute
UCL Great Ormond Street Institute of Child Health
UltraHuman
UMC Utrecht
Umea Biotech Incubator
Umea University
Univ of Ljubljana Biotechnical Fac
University College London
University Medical Center Utrecht
University of Lisbon
University of Montpellier
University of Southampton
University of Zurich
Utrecht University
Weizmann Institute of Science
WuXi Biologics
Zymeworks
CONNECT WITH KEY BUYERS AT Antibody Europe 2020 in Amsterdam
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact Kristin Skahan: KSkahan@knect365lifesciences.com | +1-857-504-6730
About The Antibody Society
The Antibody Society is an international, non-profit representing individuals and organizations involved in antibody-related research and development. The Society has a variety of initiatives and working groups focused on improving the antibody field.
We are:
- Creating opportunities for education and networking;
- Monitoring and reporting advances in the commercial pipeline for antibody and CAR-T therapeutics;
- Creating standards for characterizing antibody and T-cell receptor repertoires, and engaging this field;
- Engaging government and international agencies on matters concerning the antibody community;
Please join us!
